Related references
Note: Only part of the references are listed.Macrophage-derived CXCL9 and CXCL11, T-cell skin homing, and disease control in mogamulizumab-treated CTCL patients
Adele de Masson et al.
BLOOD (2022)
Clinical Characterization of Mogamulizumab-Associated Rash During Treatment of Mycosis Fungoides or Sezary Syndrome
Kelsey E. Hirotsu et al.
JAMA DERMATOLOGY (2021)
Complete response following toxic epidermal necrolysis in relapsed adult T cell leukemia/lymphoma after haploidentical stem cell transplantation
Satoshi Morishige et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2019)
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial
Youn H. Kim et al.
LANCET ONCOLOGY (2018)
Late onset toxic epidermal necrolysis induced by mogamulizumab, an anti-CC chemokine receptor 4 antibody for the treatment of adult T-cell leukaemia/lymphoma
Souichi Shiratori et al.
HEMATOLOGICAL ONCOLOGY (2017)
Toxic epidermal necrolysis in adult T cell leukemia/lymphoma treated with mogamulizumab
Kazuna Tanba et al.
ANNALS OF HEMATOLOGY (2016)
StevensJohnson Syndrome associated with mogamulizumab treatment of adult T-cell leukemia/lymphoma
Takashi Ishida et al.
CANCER SCIENCE (2013)
A 9-centimorgan interval of chromosome 10 controls the T cell-dependent psoriasiform skin disease and arthritis in a murine psoriasis model
Honglin Wang et al.
JOURNAL OF IMMUNOLOGY (2008)